BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:HIV readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in HIV\, from ClinicalTr
 ials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04892654-960@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Pifeltro (Doravirine): Phase 3 readout est. (NCT04892654)
DESCRIPTION:Pifeltro (Doravirine)\, phase 3\, HIV.\nStudy: Efficacy of Dora
 virine + Dolutegravir Dual Therapy in the Context of Antiretroviral Therap
 y Switch\nEstimated primary completion: 30 November 2026. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/doravirine#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT04892654
URL:https://assetmemo.bio/drug/doravirine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04892654-1031@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Tivicay / Triumeq / Dovato / Juluca (component) (Dolutegravir): Pha
 se 3 readout est. (NCT04892654)
DESCRIPTION:Tivicay / Triumeq / Dovato / Juluca (component) (Dolutegravir)\
 , phase 3\, HIV.\nStudy: Efficacy of Doravirine + Dolutegravir Dual Therap
 y in the Context of Antiretroviral Therapy Switch\nEstimated primary compl
 etion: 30 November 2026. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/dolutegravir#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT04892654
URL:https://assetmemo.bio/drug/dolutegravir#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04985890-1019@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Semzuvolimab: Phase 2 readout est. (NCT04985890)
DESCRIPTION:Semzuvolimab\, phase 2\, HIV.\nStudy: A Proof of Concept Study 
 to Evaluate the Effect of UB-421 in Combination With Chidamide on HIV Vira
 l Reservoir\nEstimated primary completion: December 2026. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/semzuvolimab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT04985890
URL:https://assetmemo.bio/drug/semzuvolimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07308782-1025@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:CL-197: Phase 2 readout est. (NCT07308782)
DESCRIPTION:CL-197\, phase 2\, HIV.\nStudy: A Phase Ⅱa Clinical Study of 
 CL-197 Capsules\nEstimated primary completion: December 2026. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/cl-197#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07308782
URL:https://assetmemo.bio/drug/cl-197#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06747507-1031@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Tivicay / Triumeq / Dovato / Juluca (component) (Dolutegravir): Pha
 se 3 readout est. (NCT06747507)
DESCRIPTION:Tivicay / Triumeq / Dovato / Juluca (component) (Dolutegravir)\
 , phase 3\, HIV.\nStudy: Ndovu RCT: Investing the Optimal Management of Do
 lutegravir Resistance\nEstimated primary completion: December 2026. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/dolutegravir#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06747507
URL:https://assetmemo.bio/drug/dolutegravir#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06774872-960@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20270115
DTEND;VALUE=DATE:20270116
SUMMARY:Pifeltro (Doravirine): Phase 2 readout est. (NCT06774872)
DESCRIPTION:Pifeltro (Doravirine)\, phase 2\, HIV.\nStudy: Doravirine/Lamiv
 udine (DOR/3TC) as a Maintenance ART in Comparison With Dolutegravir/Lamiv
 udine (DTG/3TC) in PLWH Successfully\nEstimated primary completion: 15 Jan
 uary 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/doravirine
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT067
 74872
URL:https://assetmemo.bio/drug/doravirine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07579741-1003@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20270212
DTEND;VALUE=DATE:20270213
SUMMARY:JL18008: Phase 1/2 readout est. (NCT07579741)
DESCRIPTION:JL18008\, phase 1/2\, HIV.\nStudy: A Study to Evaluate JL18008 
 in Subject With HIV Immunological Non-Responders\nEstimated primary comple
 tion: 12 February 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/jl18008#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07579741
URL:https://assetmemo.bio/drug/jl18008#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06411223-957@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Cabotegravir/rilpivirine (Cabenuva): Phase 2 readout est. (NCT06411
 223)
DESCRIPTION:Cabotegravir/rilpivirine (Cabenuva)\, phase 2\, HIV.\nStudy: Ph
 armacist-led Intervention for Injectable HIV Treatment for Women With Heal
 th-related Social Needs\nEstimated primary completion: March 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/cabotegravir-rilpivirine-cab
 enuva#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06411223
URL:https://assetmemo.bio/drug/cabotegravir-rilpivirine-cabenuva#upcoming-e
 vents
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06749054-966@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Lenacapavir (Sunlenca): Phase 2 readout est. (NCT06749054)
DESCRIPTION:Lenacapavir (Sunlenca)\, phase 2\, HIV.\nStudy: Evaluation of L
 ong-Acting Lenacapavir for the Treatment of HIV-1 in Treatment-experienced
  Adolescents and Children\nEstimated primary completion: March 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/lenacapavir-sunlenca#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT06749054
URL:https://assetmemo.bio/drug/lenacapavir-sunlenca#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06805656-967@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Selzentry / Celsentri (Maraviroc): Phase 2 readout est. (NCT0680565
 6)
DESCRIPTION:Selzentry / Celsentri (Maraviroc)\, phase 2\, HIV.\nStudy: Mult
 i Interventional Approaches to Mitigate HIV Reservoirs for the Sustained H
 IV Remission Without Antiretrovirals\nEstimated primary completion: 1 Marc
 h 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/maraviroc#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0680565
 6
URL:https://assetmemo.bio/drug/maraviroc#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06805656-1031@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Tivicay / Triumeq / Dovato / Juluca (component) (Dolutegravir): Pha
 se 2 readout est. (NCT06805656)
DESCRIPTION:Tivicay / Triumeq / Dovato / Juluca (component) (Dolutegravir)\
 , phase 2\, HIV.\nStudy: Multi Interventional Approaches to Mitigate HIV R
 eservoirs for the Sustained HIV Remission Without Antiretrovirals\nEstimat
 ed primary completion: 1 March 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/dolutegravir#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06805656
URL:https://assetmemo.bio/drug/dolutegravir#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07215468-1017@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:TMB-365 / TMB-380: Phase 2 readout est. (NCT07215468)
DESCRIPTION:TMB-365 / TMB-380\, phase 2\, HIV.\nStudy: HIV-1 Virologic Supp
 ression With TMB-365 and TMB-380 Antibodies Study\nEstimated primary compl
 etion: May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tmb-
 365-tmb-380#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07215468
URL:https://assetmemo.bio/drug/tmb-365-tmb-380#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07711210-991@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:ACC017: Phase 1/2 readout est. (NCT07711210)
DESCRIPTION:ACC017\, phase 1/2\, HIV.\nStudy: Efficacy and Safety of the AC
 C017-Based Antiretroviral Regimen in Treatment-Experienced Adults With HIV
 -1 Harboring Non-Nucleoside Reverse Transcriptase Inhibitor Resistance Mut
 ations\nEstimated primary completion: 30 June 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/acc017#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07711210
URL:https://assetmemo.bio/drug/acc017#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07044297-1010@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20270722
DTEND;VALUE=DATE:20270723
SUMMARY:Alimatravir: Phase 3 readout est. (NCT07044297)
DESCRIPTION:Alimatravir\, phase 3\, HIV.\nStudy: A Clinical Study of MK-852
 7 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)\nEs
 timated primary completion: 22 July 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/alimatravir#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07044297
URL:https://assetmemo.bio/drug/alimatravir#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05470491-967@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Selzentry / Celsentri (Maraviroc): Phase 1/2 readout est. (NCT05470
 491)
DESCRIPTION:Selzentry / Celsentri (Maraviroc)\, phase 1/2\, HIV.\nStudy: Tr
 ial of Allogeneic Reduced-Intensity\, HLA-Haploidentical Allogeneic Hemato
 poietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Dis
 ease (GVHD) Prophylaxis With Cyclophosphamide\, Bortezomib and Maraviroc f
 or Hematologic Malignancies ...\nEstimated primary completion: 30 July 202
 7. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/maraviroc#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT05470491
URL:https://assetmemo.bio/drug/maraviroc#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07645287-966@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Lenacapavir (Sunlenca): Phase 2 readout est. (NCT07645287)
DESCRIPTION:Lenacapavir (Sunlenca)\, phase 2\, HIV.\nStudy: A Study of GS-3
 242 in Combination With Lenacapavir Versus Biktarvy in Virologically Suppr
 essed People With HIV-1\nEstimated primary completion: August 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/lenacapavir-sunlenca#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07645287
URL:https://assetmemo.bio/drug/lenacapavir-sunlenca#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07841990-966@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Lenacapavir (Sunlenca): Phase 2 readout est. (NCT07841990)
DESCRIPTION:Lenacapavir (Sunlenca)\, phase 2\, HIV.\nStudy: Substudy-01: A 
 Study of Long-Acting HIV-1 Treatments Taken by Mouth in People With HIV-1 
 With Undetectable Virus Levels\nEstimated primary completion: August 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/lenacapavir-sunlenca
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT078
 41990
URL:https://assetmemo.bio/drug/lenacapavir-sunlenca#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07645287-969@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Descovy (Tenofovir alafenamide/emtricitabine): Phase 2 readout est.
  (NCT07645287)
DESCRIPTION:Descovy (Tenofovir alafenamide/emtricitabine)\, phase 2\, HIV.\
 nStudy: A Study of GS-3242 in Combination With Lenacapavir Versus Biktarvy
  in Virologically Suppressed People With HIV-1\nEstimated primary completi
 on: August 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/teno
 fovir-alafenamide-emtricitabine#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07645287
URL:https://assetmemo.bio/drug/tenofovir-alafenamide-emtricitabine#upcoming
 -events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06891066-965@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20270810
DTEND;VALUE=DATE:20270811
SUMMARY:Islatravir: Phase 2 readout est. (NCT06891066)
DESCRIPTION:Islatravir\, phase 2\, HIV.\nStudy: A Study of Islatravir (ISL)
  and Ulonivirine (ULO) Once Weekly (QW) in Virologically Suppressed Adults
  With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8591B-060)\nEstimate
 d primary completion: 10 August 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/islatravir#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06891066
URL:https://assetmemo.bio/drug/islatravir#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06891066-1021@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20270810
DTEND;VALUE=DATE:20270811
SUMMARY:Ulonivirine: Phase 2 readout est. (NCT06891066)
DESCRIPTION:Ulonivirine\, phase 2\, HIV.\nStudy: A Study of Islatravir (ISL
 ) and Ulonivirine (ULO) Once Weekly (QW) in Virologically Suppressed Adult
 s With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8591B-060)\nEstimat
 ed primary completion: 10 August 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/ulonivirine#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06891066
URL:https://assetmemo.bio/drug/ulonivirine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07071623-1010@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20271018
DTEND;VALUE=DATE:20271019
SUMMARY:Alimatravir: Phase 3 readout est. (NCT07071623)
DESCRIPTION:Alimatravir\, phase 3\, HIV.\nStudy: A Study of MK-8527 to Prev
 ent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010)\nEstimated p
 rimary completion: 18 October 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/alimatravir#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07071623
URL:https://assetmemo.bio/drug/alimatravir#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07202546-978@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20271028
DTEND;VALUE=DATE:20271029
SUMMARY:VH4524184: Phase 2 readout est. (NCT07202546)
DESCRIPTION:VH4524184\, phase 2\, HIV.\nStudy: A Phase 2b Study Evaluating 
 Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE S
 tudy)\nEstimated primary completion: 28 October 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/vh4524184#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07202546
URL:https://assetmemo.bio/drug/vh4524184#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07054931-981@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Teropavimab: Phase 2 readout est. (NCT07054931)
DESCRIPTION:Teropavimab\, phase 2\, HIV.\nStudy: Combination Vaccination an
 d Broadly Neutralising Antibody Therapy in HIV\nEstimated primary completi
 on: 31 October 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 teropavimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07054931
URL:https://assetmemo.bio/drug/teropavimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07054931-982@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Zinlirvimab: Phase 2 readout est. (NCT07054931)
DESCRIPTION:Zinlirvimab\, phase 2\, HIV.\nStudy: Combination Vaccination an
 d Broadly Neutralising Antibody Therapy in HIV\nEstimated primary completi
 on: 31 October 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 zinlirvimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07054931
URL:https://assetmemo.bio/drug/zinlirvimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07850609-1010@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20271202
DTEND;VALUE=DATE:20271203
SUMMARY:Alimatravir: Phase 2 readout est. (NCT07850609)
DESCRIPTION:Alimatravir\, phase 2\, HIV.\nStudy: A Clinical Study of Alimat
 ravir (MK-8527) in Transgender (Trans) and Gender Diverse Individuals on G
 ender-affirming Hormone Therapy and at Low Likelihood of Human Immunodefic
 iency Virus (HIV)-1 Exposure (MK-8527-018)\nEstimated primary completion: 
 2 December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/alim
 atravir#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07850609
URL:https://assetmemo.bio/drug/alimatravir#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07075146-960@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20271205
DTEND;VALUE=DATE:20271206
SUMMARY:Pifeltro (Doravirine): Phase 3 readout est. (NCT07075146)
DESCRIPTION:Pifeltro (Doravirine)\, phase 3\, HIV.\nStudy: DOR/TDF/3TC COmp
 ared With BIC/FTC/TAF in ART-Naïve People Living With HIV and Overweight 
 or Obesity\nEstimated primary completion: 5 December 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/doravirine#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07075146
URL:https://assetmemo.bio/drug/doravirine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07075146-8395@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20271205
DTEND;VALUE=DATE:20271206
SUMMARY:Tenofovir disoproxil fumarate (Viread): Phase 3 readout est. (NCT07
 075146)
DESCRIPTION:Tenofovir disoproxil fumarate (Viread)\, phase 3\, HIV.\nStudy:
  DOR/TDF/3TC COmpared With BIC/FTC/TAF in ART-Naïve People Living With HI
 V and Overweight or Obesity\nEstimated primary completion: 5 December 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/tenofovir-disoproxi
 l-fumarate-viread#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07075146
URL:https://assetmemo.bio/drug/tenofovir-disoproxil-fumarate-viread#upcomin
 g-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05813964-969@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Descovy (Tenofovir alafenamide/emtricitabine): Phase 3 readout est.
  (NCT05813964)
DESCRIPTION:Descovy (Tenofovir alafenamide/emtricitabine)\, phase 3\, HIV.\
 nStudy: Efficacy\, Acceptability and Safety of Event-driven HIV PrEP Using
  TAF/FTC in MSM in Thailand and France.\nEstimated primary completion: 31 
 December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tenofo
 vir-alafenamide-emtricitabine#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT05813964
URL:https://assetmemo.bio/drug/tenofovir-alafenamide-emtricitabine#upcoming
 -events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06203132-960@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Pifeltro (Doravirine): Phase 3 readout est. (NCT06203132)
DESCRIPTION:Pifeltro (Doravirine)\, phase 3\, HIV.\nStudy: DORAvirine Versu
 s DOlutegravir Based Antiretroviral Regimens in Treatment-naïve People Li
 ving With HIV-1 Infection\nEstimated primary completion: January 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/doravirine#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06203132
URL:https://assetmemo.bio/drug/doravirine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06203132-8395@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Tenofovir disoproxil fumarate (Viread): Phase 3 readout est. (NCT06
 203132)
DESCRIPTION:Tenofovir disoproxil fumarate (Viread)\, phase 3\, HIV.\nStudy:
  DORAvirine Versus DOlutegravir Based Antiretroviral Regimens in Treatment
 -naïve People Living With HIV-1 Infection\nEstimated primary completion: 
 January 2028. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tenofov
 ir-disoproxil-fumarate-viread#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06203132
URL:https://assetmemo.bio/drug/tenofovir-disoproxil-fumarate-viread#upcomin
 g-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02140255-968@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Isentress (Raltegravir): Phase 1/2 readout est. (NCT02140255)
DESCRIPTION:Isentress (Raltegravir)\, phase 1/2\, HIV.\nStudy: Very Early I
 ntensive Treatment of Infants Living With HIV to Achieve HIV Remission\nEs
 timated primary completion: 31 January 2028. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/raltegravir#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT02140255
URL:https://assetmemo.bio/drug/raltegravir#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02140255-1031@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Tivicay / Triumeq / Dovato / Juluca (component) (Dolutegravir): Pha
 se 1/2 readout est. (NCT02140255)
DESCRIPTION:Tivicay / Triumeq / Dovato / Juluca (component) (Dolutegravir)\
 , phase 1/2\, HIV.\nStudy: Very Early Intensive Treatment of Infants Livin
 g With HIV to Achieve HIV Remission\nEstimated primary completion: 31 Janu
 ary 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dolutegravi
 r#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT02
 140255
URL:https://assetmemo.bio/drug/dolutegravir#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06497465-1031@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Tivicay / Triumeq / Dovato / Juluca (component) (Dolutegravir): Pha
 se 3 readout est. (NCT06497465)
DESCRIPTION:Tivicay / Triumeq / Dovato / Juluca (component) (Dolutegravir)\
 , phase 3\, HIV.\nStudy: Dolutegravir/Lamivudine Dual Therapy for ART-naï
 ve People With HIV and TB Receiving Rifampin-based TB Treatment\nEstimated
  primary completion: 31 January 2028. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/dolutegravir#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06497465
URL:https://assetmemo.bio/drug/dolutegravir#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07871552-960@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20280415
DTEND;VALUE=DATE:20280416
SUMMARY:Pifeltro (Doravirine): Phase 2 readout est. (NCT07871552)
DESCRIPTION:Pifeltro (Doravirine)\, phase 2\, HIV.\nStudy: Effects of Switc
 h to Doravirine/Islatravir vs. Continued Antiretroviral Therapy on Biomark
 ers of Aging Among Virologically Suppressed People With HIV\nEstimated pri
 mary completion: 15 April 2028. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/doravirine#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07871552
URL:https://assetmemo.bio/drug/doravirine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06554717-1018@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20280616
DTEND;VALUE=DATE:20280617
SUMMARY:Egrifta WR (Tesamorelin): Phase 2 readout est. (NCT06554717)
DESCRIPTION:Egrifta WR (Tesamorelin)\, phase 2\, HIV.\nStudy: Tesamorelin a
 s an Adjunct to Exercise for Improving Physical Function in HIV\nEstimated
  primary completion: 16 June 2028. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/tesamorelin#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT06554717
URL:https://assetmemo.bio/drug/tesamorelin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07124559-1031@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20280626
DTEND;VALUE=DATE:20280627
SUMMARY:Tivicay / Triumeq / Dovato / Juluca (component) (Dolutegravir): Pha
 se 1/2 readout est. (NCT07124559)
DESCRIPTION:Tivicay / Triumeq / Dovato / Juluca (component) (Dolutegravir)\
 , phase 1/2\, HIV.\nStudy: A Study of Daily Rifapentine Combined With Ison
 iazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of 
 Age With and Without HIV\nEstimated primary completion: 26 June 2028. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/dolutegravir#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07124559
URL:https://assetmemo.bio/drug/dolutegravir#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07711223-969@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Descovy (Tenofovir alafenamide/emtricitabine): Phase 3 readout est.
  (NCT07711223)
DESCRIPTION:Descovy (Tenofovir alafenamide/emtricitabine)\, phase 3\, HIV.\
 nStudy: Efficacy and Safety of ACC017 Tablets Compared With Dolutegravir S
 odium Tablets in Treatment-Naïve Adults With Human Immunodeficiency Virus
  Type 1 (HIV-1)\nEstimated primary completion: 31 August 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/tenofovir-alafenamide-emtricitab
 ine#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07711223
URL:https://assetmemo.bio/drug/tenofovir-alafenamide-emtricitabine#upcoming
 -events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07711223-991@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:ACC017: Phase 3 readout est. (NCT07711223)
DESCRIPTION:ACC017\, phase 3\, HIV.\nStudy: Efficacy and Safety of ACC017 T
 ablets Compared With Dolutegravir Sodium Tablets in Treatment-Naïve Adult
 s With Human Immunodeficiency Virus Type 1 (HIV-1)\nEstimated primary comp
 letion: 31 August 2028. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/acc017#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07711223
URL:https://assetmemo.bio/drug/acc017#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07047716-11049@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Lenacapavir (Yeztugo): Phase 3 readout est. (NCT07047716)
DESCRIPTION:Lenacapavir (Yeztugo)\, phase 3\, HIV.\nStudy: Study of Lenacap
 avir as a Once-Yearly Injection for HIV Pre-exposure Prophylaxis (PrEP)\nE
 stimated primary completion: September 2028. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/lenacapavir-yeztugo#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07047716
URL:https://assetmemo.bio/drug/lenacapavir-yeztugo#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07030920-963@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Rukobia (Fostemsavir): Phase 2 readout est. (NCT07030920)
DESCRIPTION:Rukobia (Fostemsavir)\, phase 2\, HIV.\nStudy: Reducing Systemi
 c Inflammation in People on Antiretroviral Therapy\nEstimated primary comp
 letion: October 2028. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /fostemsavir#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07030920
URL:https://assetmemo.bio/drug/fostemsavir#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04375800-960@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20281112
DTEND;VALUE=DATE:20281113
SUMMARY:Pifeltro (Doravirine): Phase 2 readout est. (NCT04375800)
DESCRIPTION:Pifeltro (Doravirine)\, phase 2\, HIV.\nStudy: Doravirine (DOR)
  in Human Immunodeficiency Virus (HIV)-Infected Children Aged 4 Weeks to <
 12 Years and <45 kg (MK-1439-066)\nEstimated primary completion: 12 Novemb
 er 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/doravirine#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT04375
 800
URL:https://assetmemo.bio/drug/doravirine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04375800-8395@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20281112
DTEND;VALUE=DATE:20281113
SUMMARY:Tenofovir disoproxil fumarate (Viread): Phase 2 readout est. (NCT04
 375800)
DESCRIPTION:Tenofovir disoproxil fumarate (Viread)\, phase 2\, HIV.\nStudy:
  Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children 
 Aged 4 Weeks to <12 Years and <45 kg (MK-1439-066)\nEstimated primary comp
 letion: 12 November 2028. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/tenofovir-disoproxil-fumarate-viread#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT04375800
URL:https://assetmemo.bio/drug/tenofovir-disoproxil-fumarate-viread#upcomin
 g-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04648280-963@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Rukobia (Fostemsavir): Phase 1/2 readout est. (NCT04648280)
DESCRIPTION:Rukobia (Fostemsavir)\, phase 1/2\, HIV.\nStudy: Safety and Pha
 rmacokinetics Evaluation of Fostemsavir + (OBT) in HIV-1 Infected Children
  and Adolescents Who Are Failing Their cART and Have Dual- or Triple-class
  Antiretroviral Resistance\nEstimated primary completion: December 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/fostemsavir#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT04648280
URL:https://assetmemo.bio/drug/fostemsavir#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07637877-958@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20281230
DTEND;VALUE=DATE:20281231
SUMMARY:Edurant (Rilpivirine): Phase 2 readout est. (NCT07637877)
DESCRIPTION:Edurant (Rilpivirine)\, phase 2\, HIV.\nStudy: Targeted Therapi
 es for Immunological Non-Responders in People With HIV: A Multicenter Clin
 ical Study\nEstimated primary completion: 30 December 2028. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/rilpivirine#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07637877
URL:https://assetmemo.bio/drug/rilpivirine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07266831-965@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20290201
DTEND;VALUE=DATE:20290202
SUMMARY:Islatravir: Phase 2/3 readout est. (NCT07266831)
DESCRIPTION:Islatravir\, phase 2/3\, HIV.\nStudy: A Clinical Study of Islat
 ravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Befo
 re (MK-8591B-062)\nEstimated primary completion: 1 February 2029. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/islatravir#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07266831
URL:https://assetmemo.bio/drug/islatravir#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07266831-1021@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20290201
DTEND;VALUE=DATE:20290202
SUMMARY:Ulonivirine: Phase 2/3 readout est. (NCT07266831)
DESCRIPTION:Ulonivirine\, phase 2/3\, HIV.\nStudy: A Clinical Study of Isla
 travir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Bef
 ore (MK-8591B-062)\nEstimated primary completion: 1 February 2029. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/ulonivirine#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07266831
URL:https://assetmemo.bio/drug/ulonivirine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07682961-966@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Lenacapavir (Sunlenca): Phase 3 readout est. (NCT07682961)
DESCRIPTION:Lenacapavir (Sunlenca)\, phase 3\, HIV.\nStudy: Study of Lenaca
 pavir\, Teropavimab\, and Zinlirvimab Versus Cabotegravir and Rilpivirine 
 in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral
  Therapy\nEstimated primary completion: March 2029. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/lenacapavir-sunlenca#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07682961
URL:https://assetmemo.bio/drug/lenacapavir-sunlenca#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07683000-966@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Lenacapavir (Sunlenca): Phase 3 readout est. (NCT07683000)
DESCRIPTION:Lenacapavir (Sunlenca)\, phase 3\, HIV.\nStudy: Study of Lenaca
 pavir\, Teropavimab\, and Zinlirvimab in Virologically Suppressed Adults W
 ith HIV-1 on Stable Oral Treatment Regimens\nEstimated primary completion:
  March 2029. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/lenacapa
 vir-sunlenca#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07683000
URL:https://assetmemo.bio/drug/lenacapavir-sunlenca#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07682961-981@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Teropavimab: Phase 3 readout est. (NCT07682961)
DESCRIPTION:Teropavimab\, phase 3\, HIV.\nStudy: Study of Lenacapavir\, Ter
 opavimab\, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologi
 cally Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy\nE
 stimated primary completion: March 2029. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/teropavimab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07682961
URL:https://assetmemo.bio/drug/teropavimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07683000-981@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Teropavimab: Phase 3 readout est. (NCT07683000)
DESCRIPTION:Teropavimab\, phase 3\, HIV.\nStudy: Study of Lenacapavir\, Ter
 opavimab\, and Zinlirvimab in Virologically Suppressed Adults With HIV-1 o
 n Stable Oral Treatment Regimens\nEstimated primary completion: March 2029
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/teropavimab#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07683000
URL:https://assetmemo.bio/drug/teropavimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07682961-982@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Zinlirvimab: Phase 3 readout est. (NCT07682961)
DESCRIPTION:Zinlirvimab\, phase 3\, HIV.\nStudy: Study of Lenacapavir\, Ter
 opavimab\, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologi
 cally Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy\nE
 stimated primary completion: March 2029. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/zinlirvimab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07682961
URL:https://assetmemo.bio/drug/zinlirvimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07683000-982@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Zinlirvimab: Phase 3 readout est. (NCT07683000)
DESCRIPTION:Zinlirvimab\, phase 3\, HIV.\nStudy: Study of Lenacapavir\, Ter
 opavimab\, and Zinlirvimab in Virologically Suppressed Adults With HIV-1 o
 n Stable Oral Treatment Regimens\nEstimated primary completion: March 2029
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/zinlirvimab#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07683000
URL:https://assetmemo.bio/drug/zinlirvimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06134362-11050@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20290314
DTEND;VALUE=DATE:20290315
SUMMARY:Cabotegravir (Apretude): Phase 3 readout est. (NCT06134362)
DESCRIPTION:Cabotegravir (Apretude)\, phase 3\, HIV.\nStudy: Long-term Foll
 ow-up of Long-acting Cabotegravir (CAB LA) for PrEP (Pre-exposure Prophyla
 xis) in Participants at Risk of Acquiring HIV (Human Immunodeficiency Viru
 s)\nEstimated primary completion: 14 March 2029. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/cabotegravir-apretude#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06134362
URL:https://assetmemo.bio/drug/cabotegravir-apretude#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04776252-10993@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20290529
DTEND;VALUE=DATE:20290530
SUMMARY:Doravirine/islatravir (Idvynso): Phase 3 readout est. (NCT04776252)
DESCRIPTION:Doravirine/islatravir (Idvynso)\, phase 3\, HIV.\nStudy: Open-l
 abel\, Follow-up of Doravirine/Islatravir (DOR/ISL 100 mg/0.75mg) for Part
 icipants With Human Immunodeficiency Virus-1 (HIV-1) Infection (MK-8591A-0
 33)\nEstimated primary completion: 29 May 2029. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/doravirine-islatravir-idvynso#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT04776252
URL:https://assetmemo.bio/drug/doravirine-islatravir-idvynso#upcoming-event
 s
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07792096-959@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Prezista (Darunavir): Phase 3 readout est. (NCT07792096)
DESCRIPTION:Prezista (Darunavir)\, phase 3\, HIV.\nStudy: An Adaptive Platf
 orm Trial for Evaluation of Novel Treatment Regimens in Children and Adole
 scents With HIV in Africa\nEstimated primary completion: June 2029. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/darunavir#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07792096
URL:https://assetmemo.bio/drug/darunavir#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07792096-1031@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Tivicay / Triumeq / Dovato / Juluca (component) (Dolutegravir): Pha
 se 3 readout est. (NCT07792096)
DESCRIPTION:Tivicay / Triumeq / Dovato / Juluca (component) (Dolutegravir)\
 , phase 3\, HIV.\nStudy: An Adaptive Platform Trial for Evaluation of Nove
 l Treatment Regimens in Children and Adolescents With HIV in Africa\nEstim
 ated primary completion: June 2029. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/dolutegravir#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07792096
URL:https://assetmemo.bio/drug/dolutegravir#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07792096-9911@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Emtricitabine (Emtriva): Phase 3 readout est. (NCT07792096)
DESCRIPTION:Emtricitabine (Emtriva)\, phase 3\, HIV.\nStudy: An Adaptive Pl
 atform Trial for Evaluation of Novel Treatment Regimens in Children and Ad
 olescents With HIV in Africa\nEstimated primary completion: June 2029. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/emtricitabine-emtriva#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT077920
 96
URL:https://assetmemo.bio/drug/emtricitabine-emtriva#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07650916-957@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20290813
DTEND;VALUE=DATE:20290814
SUMMARY:Cabotegravir/rilpivirine (Cabenuva): Phase 3 readout est. (NCT07650
 916)
DESCRIPTION:Cabotegravir/rilpivirine (Cabenuva)\, phase 3\, HIV.\nStudy: A 
 Study to Investigate Cabotegravir Ultra Long-Acting (CAB ULA) Plus Rilpivi
 rine Ultra Long-Acting (RPV ULA) in Adults and Adolescents With HIV Who Ar
 e Virologically Suppressed\nEstimated primary completion: 13 August 2029. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/cabotegravir-rilpivir
 ine-cabenuva#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07650916
URL:https://assetmemo.bio/drug/cabotegravir-rilpivirine-cabenuva#upcoming-e
 vents
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07275606-957@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20291010
DTEND;VALUE=DATE:20291011
SUMMARY:Cabotegravir/rilpivirine (Cabenuva): Phase 1/2 readout est. (NCT072
 75606)
DESCRIPTION:Cabotegravir/rilpivirine (Cabenuva)\, phase 1/2\, HIV.\nStudy: 
 A Study to Investigate Cabotegravir for Neonates Exposed to HIV-1\nEstimat
 ed primary completion: 10 October 2029. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/cabotegravir-rilpivirine-cabenuva#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07275606
URL:https://assetmemo.bio/drug/cabotegravir-rilpivirine-cabenuva#upcoming-e
 vents
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06532656-11020@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20300731
DTEND;VALUE=DATE:20300801
SUMMARY:Bictegravir/lenacapavir (Bixlenvo): Phase 2/3 readout est. (NCT0653
 2656)
DESCRIPTION:Bictegravir/lenacapavir (Bixlenvo)\, phase 2/3\, HIV.\nStudy: S
 tudy of Bictegravir/Lenacapavir in Children and Adolescents With HIV-1\nEs
 timated primary completion: July 2030. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/bictegravir-lenacapavir-bixlenvo#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06532656
URL:https://assetmemo.bio/drug/bictegravir-lenacapavir-bixlenvo#upcoming-ev
 ents
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07708727-966@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20301031
DTEND;VALUE=DATE:20301101
SUMMARY:Lenacapavir (Sunlenca): Phase 2/3 readout est. (NCT07708727)
DESCRIPTION:Lenacapavir (Sunlenca)\, phase 2/3\, HIV.\nStudy: Study of an I
 njectable Regimen of GS-3242 With Lenacapavir Compared to Biktarvy in Peop
 le New to HIV-1 Treatment\nEstimated primary completion: October 2030. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/lenacapavir-sunlenca#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0770872
 7
URL:https://assetmemo.bio/drug/lenacapavir-sunlenca#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07708727-969@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20301031
DTEND;VALUE=DATE:20301101
SUMMARY:Descovy (Tenofovir alafenamide/emtricitabine): Phase 2/3 readout es
 t. (NCT07708727)
DESCRIPTION:Descovy (Tenofovir alafenamide/emtricitabine)\, phase 2/3\, HIV
 .\nStudy: Study of an Injectable Regimen of GS-3242 With Lenacapavir Compa
 red to Biktarvy in People New to HIV-1 Treatment\nEstimated primary comple
 tion: October 2030. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/t
 enofovir-alafenamide-emtricitabine#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07708727
URL:https://assetmemo.bio/drug/tenofovir-alafenamide-emtricitabine#upcoming
 -events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07816250-957@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20320610
DTEND;VALUE=DATE:20320611
SUMMARY:Cabotegravir/rilpivirine (Cabenuva): Phase 2 readout est. (NCT07816
 250)
DESCRIPTION:Cabotegravir/rilpivirine (Cabenuva)\, phase 2\, HIV.\nStudy: A 
 Phase 2b Study Evaluating VH4011499 Capsid Inhibitor Long-Acting Injectabl
 e Plus Cabotegravir in Treatment Naïve Adults (CINERGY)\nEstimated primar
 y completion: 10 June 2032. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/cabotegravir-rilpivirine-cabenuva#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07816250
URL:https://assetmemo.bio/drug/cabotegravir-rilpivirine-cabenuva#upcoming-e
 vents
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07816250-977@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20320610
DTEND;VALUE=DATE:20320611
SUMMARY:Dezecapavir: Phase 2 readout est. (NCT07816250)
DESCRIPTION:Dezecapavir\, phase 2\, HIV.\nStudy: A Phase 2b Study Evaluatin
 g VH4011499 Capsid Inhibitor Long-Acting Injectable Plus Cabotegravir in T
 reatment Naïve Adults (CINERGY)\nEstimated primary completion: 10 June 20
 32. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/dezecapavir#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07816250
URL:https://assetmemo.bio/drug/dezecapavir#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07393659-963@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20320914
DTEND;VALUE=DATE:20320915
SUMMARY:Rukobia (Fostemsavir): Phase 3 readout est. (NCT07393659)
DESCRIPTION:Rukobia (Fostemsavir)\, phase 3\, HIV.\nStudy: A Continued Acce
 ss Study for Participants Transitioning From ViiV Healthcare-sponsored or 
 ViiV Healthcare-collaborative Parent Studies for HIV Treatment\nEstimated 
 primary completion: 14 September 2032. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/fostemsavir#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07393659
URL:https://assetmemo.bio/drug/fostemsavir#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07393659-1031@assetmemo.bio
DTSTAMP:20261121T004009Z
DTSTART;VALUE=DATE:20320914
DTEND;VALUE=DATE:20320915
SUMMARY:Tivicay / Triumeq / Dovato / Juluca (component) (Dolutegravir): Pha
 se 3 readout est. (NCT07393659)
DESCRIPTION:Tivicay / Triumeq / Dovato / Juluca (component) (Dolutegravir)\
 , phase 3\, HIV.\nStudy: A Continued Access Study for Participants Transit
 ioning From ViiV Healthcare-sponsored or ViiV Healthcare-collaborative Par
 ent Studies for HIV Treatment\nEstimated primary completion: 14 September 
 2032. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/dolutegravir#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT073936
 59
URL:https://assetmemo.bio/drug/dolutegravir#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
